Latest long-term debt for CYTHW: $7.1K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest long-term debt for CYTHW is $7.1K as of September 2024. That compares with $27K in the prior-year period — down 73.8% year over year. Investors often review this figure alongside Cyclo Therapeutics- Warrants (14/11/2025)'s historical trend and sector peers before judging valuation or financial health.
Over the past year, CYTHW's long-term debt moved from $27K to $7.1K — a 73.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cyclo Therapeutics- Warrants (14/11/2025)'s operating scale or balance-sheet position.
A long-term debt figure of $7.1K for CYTHW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting CYTHW's long-term debt ($7.1K), review year-over-year change from $27K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cyclo Therapeutics- Warrants (14/11/2025)'s long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.